News & Updates

Show Multimedia Only

Statins reduce MACE in patients with normal MPI, elevated CAC score

14 Feb 2023 by

Use of moderate to high-intensity statin (MHIS) following myocardial perfusion imaging (MPI) results in fewer major adverse cardiovascular events (MACE) and is independently predictive of 24-month MACE among patients with normal stress MPI and coronary artery calcium (CAC) score >300, a Singapore study has shown.

Statins reduce MACE in patients with normal MPI, elevated CAC score

14 Feb 2023

P2Y12 inhibitor monotherapy on par with DAPT after complex PCI

14 Feb 2023

Compared with standard dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy after 1- to 3-month DAPT results in similar rates of fatal and ischaemic events, as well as lower major bleeding risk, regardless of percutaneous coronary intervention (PCI) complexity, according to a study.

P2Y12 inhibitor monotherapy on par with DAPT after complex PCI

14 Feb 2023

Infrequent inclisiran dosing effective for lipid-lowering in the primary prevention setting

14 Feb 2023 by

Twice-yearly maintenance dosing of inclisiran reduces atherogenic lipoproteins for primary prevention of patients with elevated LDL-C* despite statin use, according to the analysis of the primary prevention cohort from the ORION-11 trial.

Infrequent inclisiran dosing effective for lipid-lowering in the primary prevention setting

14 Feb 2023

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

14 Feb 2023 by

The use of liposomal irinotecan in combination with 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX regimen) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) compared with gemcitabine plus nab-paclitaxel (Gem+NabP) in the first-line setting, according to the NAPOLI-3* trial presented at the ASCO GI 2023.

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

14 Feb 2023

$Hyaluronic acid rectal spacer improves safety outcomes of hypofractionated RT for prostate cancer$

Hyaluronic acid rectal spacer improves safety outcomes of hypofractionated RT for prostate cancer

13 Feb 2023

Rectal spacing with hyaluronic acid helps lessen rectal dosimetry and mitigate the gastrointestinal (GI) toxicity associated with hypofractionated radiation therapy (RT) for prostate cancer, according to a study.

Hyaluronic acid rectal spacer improves safety outcomes of hypofractionated RT for prostate cancer

13 Feb 2023

Early antibiotics does not prevent infection in hospitalized cirrhosis patients

13 Feb 2023 by

Antibiotics are usually prescribed by physicians to patients hospitalized with decompensated cirrhosis even without an infection diagnosis, according to a UK study. However, this practice has neither reduced the overall risk of hospital-acquired infections (HAI) nor improved survival.

Early antibiotics does not prevent infection in hospitalized cirrhosis patients

13 Feb 2023

Nitrofurantoin use tied to liver injury, may lead to cirrhosis, death

13 Feb 2023

Long-term exposure to nitrofurantoin (NTF) can result in drug-induced liver injury (DILI), which then increases the risk of parenchymal necrosis, bridging fibrosis, cirrhosis, and death or liver transplantation, reveals a study. In addition, NTF-DILI is associated with HLA-DRB1∗11:04, a risk factor for liver injury.

Nitrofurantoin use tied to liver injury, may lead to cirrhosis, death

13 Feb 2023

Shorter treatment regimen feasible for rifampin-resistant TB?

13 Feb 2023 by

Individuals with rifampin-resistant tuberculosis (RR-TB) may have the option to undergo shorter treatment periods, as findings from the phase II/III TB-PRACTECAL* trial show the noninferiority and superiority of a 24-week, all-oral regimen to standard of care (SoC). It also had a better safety profile than SoC.

Shorter treatment regimen feasible for rifampin-resistant TB?

13 Feb 2023

Metformin lowers HCC risk after antiviral therapy in diabetic patients with hepatitis C

11 Feb 2023

Treatment with metformin results in a significant reduction in hepatocellular carcinoma (HCC) incidence following successful antiviral therapy in individuals with diabetes mellitus and chronic hepatitis C (CHC), a recent study has shown.

Metformin lowers HCC risk after antiviral therapy in diabetic patients with hepatitis C

11 Feb 2023

Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer

11 Feb 2023

The investigational KRAS G12C inhibitor sotorasib appears to be active against previously treated KRAS p.G12C–mutated advanced pancreatic cancer while having an acceptable safety profile, according to the results of a phase I/II trial.

Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer

11 Feb 2023

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Statins reduce MACE in patients with normal MPI, elevated CAC score

Statins reduce MACE in patients with normal MPI, elevated CAC score

P2Y12 inhibitor monotherapy on par with DAPT after complex PCI

P2Y12 inhibitor monotherapy on par with DAPT after complex PCI

Infrequent inclisiran dosing effective for lipid-lowering in the primary prevention setting

Infrequent inclisiran dosing effective for lipid-lowering in the primary prevention setting

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

Hyaluronic acid rectal spacer improves safety outcomes of hypofractionated RT for prostate cancer

Hyaluronic acid rectal spacer improves safety outcomes of hypofractionated RT for prostate cancer

Early antibiotics does not prevent infection in hospitalized cirrhosis patients

Early antibiotics does not prevent infection in hospitalized cirrhosis patients

Nitrofurantoin use tied to liver injury, may lead to cirrhosis, death

Nitrofurantoin use tied to liver injury, may lead to cirrhosis, death

Shorter treatment regimen feasible for rifampin-resistant TB?

Shorter treatment regimen feasible for rifampin-resistant TB?

Metformin lowers HCC risk after antiviral therapy in diabetic patients with hepatitis C

Metformin lowers HCC risk after antiviral therapy in diabetic patients with hepatitis C

Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer

Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer